Mirna Therapeutics (NASDAQ: SYBX) and Alimera Sciences (NASDAQ:ALIM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, earnings, risk and dividends.

Risk & Volatility

Mirna Therapeutics has a beta of 3.96, indicating that its stock price is 296% more volatile than the S&P 500. Comparatively, Alimera Sciences has a beta of 2.2, indicating that its stock price is 120% more volatile than the S&P 500.

Valuation and Earnings

This table compares Mirna Therapeutics and Alimera Sciences’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Mirna Therapeutics N/A N/A N/A ($9.59) -1.83
Alimera Sciences $35.96 million 2.61 -$16.78 million ($0.39) -3.49

Mirna Therapeutics has higher revenue, but lower earnings than Alimera Sciences. Alimera Sciences is trading at a lower price-to-earnings ratio than Mirna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Mirna Therapeutics and Alimera Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mirna Therapeutics N/A -44.70% -42.29%
Alimera Sciences -68.58% N/A -36.39%

Analyst Recommendations

This is a summary of current ratings and target prices for Mirna Therapeutics and Alimera Sciences, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mirna Therapeutics 0 2 1 0 2.33
Alimera Sciences 0 0 3 0 3.00

Mirna Therapeutics presently has a consensus target price of $19.50, suggesting a potential upside of 11.24%. Alimera Sciences has a consensus target price of $4.00, suggesting a potential upside of 194.12%. Given Alimera Sciences’ stronger consensus rating and higher probable upside, analysts clearly believe Alimera Sciences is more favorable than Mirna Therapeutics.

Institutional and Insider Ownership

37.2% of Alimera Sciences shares are owned by institutional investors. 18.6% of Mirna Therapeutics shares are owned by company insiders. Comparatively, 14.7% of Alimera Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Alimera Sciences beats Mirna Therapeutics on 8 of the 11 factors compared between the two stocks.

Mirna Therapeutics Company Profile

Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.

Alimera Sciences Company Profile

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company’s product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.

Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.